Segall Bryant & Hamill’s Thermo Fisher Scientific TMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $6.93M | Buy |
14,102
+32
| +0.2% | +$17.4K | 0.1% | 271 |
|
|
2025
Q4 | $8.15M | Sell |
14,070
-5,717
| -29% | -$3.23M | 0.11% | 256 |
|
|
2025
Q3 | $9.6M | Sell |
19,787
-1,529
| -7% | -$712K | 0.13% | 245 |
|
|
2025
Q2 | $8.64M | Sell |
21,316
-1,406
| -6% | -$588K | 0.12% | 250 |
|
|
2025
Q1 | $11.3M | Sell |
22,722
-4,514
| -17% | -$2.44M | 0.17% | 191 |
|
|
2024
Q4 | $14.2M | Sell |
27,236
-17,465
| -39% | -$9.6M | 0.19% | 162 |
|
|
2024
Q3 | $27.7M | Buy |
44,701
+24,170
| +118% | +$14.3M | 0.38% | 84 |
|
|
2024
Q2 | $11.4M | Sell |
20,531
-1,424
| -6% | -$816K | 0.2% | 168 |
|
|
2024
Q1 | $12.8M | Sell |
21,955
-3,932
| -15% | -$2.21M | 0.24% | 146 |
|
|
2023
Q4 | $13.7M | Sell |
25,887
-146,268
| -85% | -$70.8M | 0.26% | 138 |
|
|
2023
Q3 | $87.1M | Sell |
172,155
-7,567
| -4% | -$4.03M | 1.01% | 13 |
|
|
2023
Q2 | $93.8M | Sell |
179,722
-1,778
| -1% | -$959K | 0.98% | 15 |
|
|
2023
Q1 | $105M | Buy |
181,500
+10,860
| +6% | +$6.12M | 1.13% | 10 |
|
|
2022
Q4 | $94M | Sell |
170,640
-3,171
| -2% | -$1.68M | 1.05% | 12 |
|
|
2022
Q3 | $88.2M | Sell |
173,811
-21,657
| -11% | -$12.1M | 1.05% | 13 |
|
|
2022
Q2 | $106M | Buy |
195,468
+20,051
| +11% | +$11M | 1.2% | 12 |
|
|
2022
Q1 | $104M | Sell |
175,417
-1,428
| -0.8% | -$820K | 0.99% | 19 |
|
|
2021
Q4 | $118M | Buy |
176,845
+697
| +0.4% | +$435K | 1.09% | 16 |
|
|
2021
Q3 | $101M | Buy |
176,148
+662
| +0.4% | +$363K | 0.96% | 22 |
|
|
2021
Q2 | $88.6M | Buy |
175,486
+3,856
| +2% | +$1.82M | 0.86% | 22 |
|
|
2021
Q1 | $78.3M | Sell |
171,630
-6,497
| -4% | -$3.1M | 0.77% | 27 |
|
|
2020
Q4 | $83M | Sell |
178,127
-7,517
| -4% | -$3.52M | 0.92% | 20 |
|
|
2020
Q3 | $81.9M | Buy |
185,644
+8,083
| +5% | +$3.34M | 1.11% | 14 |
|
|
2020
Q2 | $64.3M | Sell |
177,561
-1,570
| -0.9% | -$526K | 1.08% | 14 |
|
|
2020
Q1 | $50.8M | Sell |
179,131
-5,535
| -3% | -$1.75M | 1.03% | 17 |
|
|
2019
Q4 | $60M | Sell |
184,666
-759
| -0.4% | -$230K | 0.93% | 21 |
|
|
2019
Q3 | $54M | Sell |
185,425
-10,561
| -5% | -$3.02M | 0.84% | 22 |
|
|
2019
Q2 | $57.5M | Sell |
195,986
-756
| -0.4% | -$208K | 0.87% | 19 |
|
|
2019
Q1 | $53.8M | Sell |
196,742
-3,015
| -2% | -$750K | 0.84% | 21 |
|
|
2018
Q4 | $44.7M | Buy |
199,757
+3,484
| +2% | +$817K | 0.77% | 26 |
|
|
2018
Q3 | $47.9M | Buy |
196,273
+8,493
| +5% | +$1.95M | 0.71% | 29 |
|
|
2018
Q2 | $38.9M | Buy |
187,780
+17,303
| +10% | +$3.67M | 0.59% | 35 |
|
|
2018
Q1 | $35.2M | Sell |
170,477
-11,748
| -6% | -$2.47M | 0.82% | 29 |
|
|
2017
Q4 | $34.6M | Buy |
182,225
+34,763
| +24% | +$6.66M | 0.76% | 35 |
|
|
2017
Q3 | $27.9M | Buy |
147,462
+145,479
| +7,336% | +$26.3M | 0.65% | 44 |
|
|
2017
Q2 | $346K | Hold |
1,983
| – | – | 0.01% | 482 |
|
|
2017
Q1 | $305K | Buy |
1,983
+124
| +7% | +$19K | 0.01% | 471 |
|
|
2016
Q4 | $262K | Hold |
1,859
| – | – | 0.01% | 494 |
|
|
2016
Q3 | $296K | Hold |
1,859
| – | – | 0.01% | 476 |
|
|
2016
Q2 | $275K | Sell |
1,859
-100
| -5% | -$14.8K | 0.01% | 488 |
|
|
2016
Q1 | $277K | Sell |
1,959
-600
| -23% | -$80.4K | 0.01% | 494 |
|
|
2015
Q4 | $363K | Buy |
2,559
+700
| +38% | +$93.4K | 0.01% | 449 |
|
|
2015
Q3 | $227K | Hold |
1,859
| – | – | 0.01% | 508 |
|
|
2015
Q2 | $241K | Hold |
1,859
| – | – | 0.01% | 509 |
|
|
2015
Q1 | $250K | Hold |
1,859
| – | – | 0.01% | 509 |
|
|
2014
Q4 | $233K | Hold |
1,859
| – | – | 0.01% | 514 |
|
|
2014
Q3 | $226K | Hold |
1,859
| – | – | 0.01% | 522 |
|
|
2014
Q2 | $219K | Sell |
1,859
-1,000
| -35% | -$118K | 0.01% | 534 |
|
|
2014
Q1 | $344K | Hold |
2,859
| – | – | 0.01% | 492 |
|
|
2013
Q4 | $318K | Hold |
2,859
| – | – | 0.01% | 508 |
|
|
2013
Q3 | $263K | Hold |
2,859
| – | – | 0.01% | 525 |
|
|
2013
Q2 | $242K | Buy |
+2,859
| New | +$238K | 0.01% | 505 |
|
Other funds holding TMO
VCM
Segall Bryant & Hamill's TMO Position: Q1 2026 in Review
Segall Bryant & Hamill increased its Thermo Fisher Scientific (TMO) stake by 0.23% in Q1 2026, buying an estimated $17.4K and bringing the position to 14,102 shares worth $6.93M. The position accounts for 0.1% of the portfolio, ranked #271.
Segall Bryant & Hamill first reported a position in TMO in Q2 2013 and has held it in 52 quarters since. The position peaked at $118M in Q4 2021. 2,587 funds tracked by Wall St. Rank hold TMO as of Q1 2026.
- Segall Bryant & Hamill held 14,102 shares of Thermo Fisher Scientific worth $6.93M as of Q1 2026.
- Segall Bryant & Hamill bought 32 Thermo Fisher Scientific shares in Q1 2026, an estimated $17.4K.
- Thermo Fisher Scientific made up 0.1% of Segall Bryant & Hamill's portfolio in Q1 2026, its #271 holding.
- Segall Bryant & Hamill first reported a position in Thermo Fisher Scientific in Q2 2013 and has held it in 52 quarters since.
- Segall Bryant & Hamill's Thermo Fisher Scientific position peaked at $118M in Q4 2021.
- 2,587 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q1 2026.
Based on Segall Bryant & Hamill's 13F filing for Q1 2026, filed 15 May 2026.